Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Operating Expenses (2024 - 2025)

Stoke Therapeutics has reported Other Operating Expenses over the past 2 years, most recently at $152.4 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 201.36% year-over-year to $152.4 million; the TTM value through Dec 2025 reached $58.5 million, up 138.9%, while the annual FY2024 figure was -$150.3 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $152.4 million at Stoke Therapeutics, up from -$44.9 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $152.4 million in Q4 2025 and troughed at -$150.3 million in Q4 2024.